Background/Objectives:
Injectable biologics (IB) have emerged as some of the most effective therapies for inflammatory skin disease and this study sought to examine the distribution of U.S. IB-prescribing dermatologists.
Methods: This study used Centers for Medicare and Medicaid Services Medicare Provider Utilization and Payment Data: Part D for 2013-2015. Primary outcome measures included the densities of dermatologists who prescribed IB (etanercept, adalimumab, ustekinumab, secukinumab) in each U.S. county for any indication, represented as the number of biologic-prescribers per 100,000 Medicare Part D beneficiaries. Each county was assigned a nine-point Rural-Urban Continuum Code (RUCC) based on size, degree of urbanization, and proximity to metropolitan areas.
The proportion of counties in each RUCC with a dermatologist who prescribes biologics was also explored.
Results: 2,992 dermatologists (26.3% of dermatologists) prescribed IB in this study.
The national density of IB-prescribing dermatologists was 7.22. Only 778 counties (24.8%) had at least one IB-prescribing dermatologist.
The densities of IBprescribing dermatologists in metropolitan counties were 8.07-8.12. The densities of IBprescribing dermatologists were 4.55 and 6.51 for urban populations of greater than 20,000 people adjacent and non-adjacent to metropolitan areas, respectively.
Urban counties with populations between 2,500-19,999 and adjacent to a metropolitan area had a density of 2.03 and urban counties with the same population and not adjacent to a metropolitan area had a density of 2.84. Completely rural or urban counties with populations under 2,500 people had densities between 2.31-2.35.
Conclusion:
There are disparities in the availability of IB-prescribing dermatologists across urban-rural geographic settings in the U.S. with greatest access in large urban areas and very limited access in more rural settings. 
